Clinical Trials in the USA / NCT03604198
Active, not recruiting
Phase 2
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
NCT03604198 · tracked via the Priya Life Science USA tracker
Condition(s) studied
Cushing Syndrome
Investigational drug(s) / intervention(s)
relacorilant: CORT125134 is supplied as capsules for oral dosing.
Study summary
This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may benefit from continuing treatment.
Eligibility
Inclusion Criteria:
* Major Inclusion Criteria:
* Have completed a Corcept-sponsored study of relacorilant in endogenous Cushing syndrome
* According to the Investigator's opinion will benefit from continuing treatment with relacorilant.
Exclusion Criteria:
* Major Exclusion Criteria:
* Premature discontinuation from a relacorilant parent study
* Has uncontrolled, clinically significant hypothyroidism or hyperthyroidism.
Primary outcome measure(s)
- Long-term safety of relacorilant — 36 months
Number of patients with treatment-emergent adverse events (TEAEs) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 or higher
Trial sites (48)
| Facility | City | Region | Status |
|---|---|---|---|
| Site 49 | Phoenix | Arizona | |
| Site 35 | Stanford | California | |
| Site 39 | Torrance | California | |
| Site 50 | Miami | Florida | |
| Site 10 | Atlanta | Georgia | |
| Site 9 | Chicago | Illinois | |
| Site 1 | Indianapolis | Indiana | |
| Site 5 | Metairie | Louisiana | |
| Site 27 | Baltimore | Maryland | |
| Site 13 | Fall River | Massachusetts | |
| Site 8 | Ann Arbor | Michigan | |
| Site 36 | Rochester | Minnesota | |
| Site 34 | Jackson | Mississippi | |
| Site 3 | St Louis | Missouri | |
| Site 55 | Reno | Nevada | |
| Site 6 | Albany | New York | |
| Site 24 | New York | New York | |
| Site 4 | Wilmington | North Carolina | |
| Site 43 | Cleveland | Ohio | |
| Site 2 | Pittsburgh | Pennsylvania | |
| Site 46 | Pittsburgh | Pennsylvania | |
| Site 11 | Dallas | Texas | |
| Site 7 | El Paso | Texas | |
| Site 32 | Fort Worth | Texas | |
| Site 12 | Houston | Texas | |
| Site 14 | Vienna | Austria | |
| Site 51 | Nova Scotia | Canada | |
| Site 16 | Munich | Germany | |
| Site 42 | Würzburg | Germany | |
| Site 20 | Ramat Gan | Israel | |
| Site 29 | Tel Aviv | Israel | |
| Site 40 | Ancona | Italy | |
| Site 44 | Messina | Italy | |
| Site 25 | Milan | Italy | |
| Site 21 | Naples | Italy | |
| Site 48 | Padova | Italy | |
| Site 52 | Torino | Italy | |
| Site 33 | Rotterdam | Netherlands | |
| Site 47 | Krakow | Poland | |
| Site 45 | Lublin | Poland |
+ 8 more sites — see the full list on the official registry below.
More Corcept Therapeutics trials in the USA
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
Active, not recruiting
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Active, not recruiting
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT03604198 on ClinicalTrials.gov ↗ ← All trials in the USA